Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fibrinolytic therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Fibrinolytic therapy. Displaying page 1 of 1.
    EudraCT Number: 2015-001092-49 Sponsor Protocol Number: VPA-03 Start Date*: 2015-06-02
    Sponsor Name:Sahlgrenska Akademien Wallenberglaboratoriet
    Full Title: Valproic acid regulation of plasma PAI-1
    Medical condition: The fibrinolytic system
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10016611 Fibrinolytic activity increased LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002056-34 Sponsor Protocol Number: RAE001#1 Start Date*: 2004-11-10
    Sponsor Name:Bradford Teaching Hospitals NHS Foundation Trust
    Full Title: Glucocorticosteroid replacement therapy and fibrinolysis in hypopituitarism
    Medical condition: Hypopituitarism
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001219-44 Sponsor Protocol Number: 1123.28 Start Date*: 2008-01-30
    Sponsor Name:Boehringer Ingelheim France
    Full Title: STREAM - STrategic Reperfusion Early After Myocardial Infarction Comparison of the efficacy and safety of a strategy of pre-hospital fibrinolytic treatment with tenecteplase and additional antipla...
    Medical condition: ST-elevation myocardial infaction within 3 hours of onset of symptoms
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064345 ST segment elevation myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Completed) GB (Completed) IT (Completed) ES (Completed) BE (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-001245-41 Sponsor Protocol Number: 2005/Diaminodiphenylsulfon/1 Start Date*: 2005-09-23
    Sponsor Name:Department of Dermatology, Hospital of the Medical University Graz
    Full Title: A single-center, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Dapsone in adult patients with cutaneous leukocytoclastic vasculitis
    Medical condition: Cutaneous leukocytoclastic vasculitis is an inflammatory vascular disease and is manifested clinically by a spectrum of cutaneous lesions, although “papable purpura” is its clinical hallmark. The p...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000412-27 Sponsor Protocol Number: ARG-CS3-001 Start Date*: 2005-08-22
    Sponsor Name:Arginox Pharmaceuticals, Inc.
    Full Title: A Phase III International Multi-center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition with Tilarginine Acetat...
    Medical condition: It is the intent of the proposed study to further evaluate the safety and efficacy of Tilarginine Acetate Injection as a novel, mortality reducing therapeutic drug for patients with cardiogenic sho...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) HU (Prematurely Ended) AT (Completed) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001642-26 Sponsor Protocol Number: LRD.2016.STREAM2 Start Date*: 2017-10-02
    Sponsor Name:Leuven Research & Development (LRD) at University of Leuven, Belgium
    Full Title: STREAM-2 (STrategic Reperfusion in elderly patients Early After Myocardial Infarction)
    Medical condition: ST-elevation myocardial infarction within 3 hours of onset of symptoms
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000011652 10064345 ST segment elevation myocardial infarction LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-002484-60 Sponsor Protocol Number: 2020-002484-6060 Start Date*: 2021-07-12
    Sponsor Name:Odense Universityhospital
    Full Title: Intrapleural Fibrinolysis and DNase versus VATS for the treatment of pleural empyema: a randomized, controlled trial.
    Medical condition: Pleural Empyema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    20.0 10021881 - Infections and infestations 10037381 Pulmonary empyema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005589-37 Sponsor Protocol Number: RMRHS0095 Start Date*: 2013-03-08
    Sponsor Name:University of Warwick
    Full Title: select-d: Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism
    Medical condition: Venous Thromboembolism and Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10007050 Cancer LLT
    14.1 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-001341-14 Sponsor Protocol Number: BAY 59-7939 / 11527 Start Date*: 2004-11-04
    Sponsor Name:Bayer HealthCare AG
    Full Title: Controlled, Double-Blind, Randomized, Dose-ranging Study of once-daily regimen of BAY59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement-ODIXaHIP-OD Study
    Medical condition: Deep Venous Thrombosis prophylaxis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10012108
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) AT (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 13:02:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA